GSK5533524 / GSK - LARVOL DELTA

A phase 1, open-label, multicenter study to investigate the safety and preliminary activity of GSK5533524 alone or in combination in adult patients with advanced solid tumors (ESMO 2026) - No abstract available

Clinical • Metastases • P1 data • Oncology • Solid Tumor

First time in human (FTIH) study to investigate the safety and preliminary activity of GSK5533524 alone or in combination in adult participants with advanced solid tumors (clinicaltrialsregister.eu) - P1 | N=52 | Not yet recruiting | Sponsor: Glaxosmithkline Research & Development Limited | N=38 ➔ 52

Enrollment change • Oncology • Solid Tumor

First time in human (FTIH) study to investigate the safety and preliminary activity of GSK5533524 alone or in combination in adult participants with advanced solid tumors (clinicaltrialsregister.eu) - P1 | N=38 | Not yet recruiting | Sponsor: Glaxosmithkline Research & Development Limited

New P1 trial • Oncology • Solid Tumor

First Time in Human (FTIH) Study to Investigate the Safety and Preliminary Activity of GSK5533524 Alone or in Combination in Adult Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=97 | Recruiting | Sponsor: GlaxoSmithKline | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Solid Tumor

First Time in Human (FTIH) Study to Investigate the Safety and Preliminary Activity of GSK5533524 Alone or in Combination in Adult Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=97 | Not yet recruiting | Sponsor: GlaxoSmithKline

New P1 trial • Oncology • Solid Tumor